[Federal Register Volume 88, Number 76 (Thursday, April 20, 2023)]
[Notices]
[Page 24386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08327]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-29-2023]


Foreign-Trade Zone (FTZ) 7, Notification of Proposed Production 
Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto 
Rico

    AbbVie Ltd., submitted a notification of proposed production 
activity to the FTZ Board (the Board) for its facility in Barceloneta, 
Puerto Rico within Subzone 7I. The notification conforming to the 
requirements of the Board's regulations (15 CFR 400.22) was received on 
April 10, 2023.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz. The proposed finished 
product(s) and material(s)/component(s) would be added to the 
production authority that the Board previously approved for the 
operation, as reflected on the Board's website.
    The proposed finished product is RINVOQ[supreg] (upadacitinib) 
tablets (duty-free).
    The proposed foreign-status material is upadacitinib active 
pharmaceutical ingredient (duty rate 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is May 30, 2023.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: April 14, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023-08327 Filed 4-19-23; 8:45 am]
BILLING CODE 3510-DS-P